KRAS and neoplasm: Despite being previously described as undruggable due to their lack of sensitivity to anti-EGFR inhibitors such as antibodies and TKIs, we showed that 89Zr-matuzumab had very high tumor uptake in KRAS mutant xenografts despite the limited basolateral availability of EGFR due to KRAS mutations.